- Data from the dose optimization trial expected soon
- ProLectin-M is positioned as the first oral antiviral sugar chemistry drug
BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the "Company"), a clinical stage biotechnology company pioneering innovative therapies for viral diseases, is pleased to announce the successful completion of its second randomized double-blind, placebo-controlled clinical trial for its leading broad-spectrum antiviral drug candidate, ProLectin-M. Data from the trial is expected to inform both the CDSCO for a phase 3 trial design and will also be submitted to the FDA pursuant to their request.
This second randomized controlled trial was designed to confirm the groundbreaking results from the Company's earlier Phase 2 study, which demonstrated that ProLectin-M achieved undetectable levels of Polymerase Chain Reaction (PCR) and infection in less than one week in treated participants. The successful execution of this third independent trial significantly strengthens the robust evidence for ProLectin-M's potential as a rapid-acting oral therapeutic for a wide range of viral infections.
The comprehensive data from this third clinical trial, including detailed safety and efficacy endpoints, is expected to be compiled for publication in a peer-reviewed medical journal. The company anticipates that the full results will be submitted for publication in the coming weeks.
"The successful completion of our third trial is a significant achievement for Bioxytran and represents a potential paradigm shift in antiviral therapy," said Dr. David Platt, CEO of Bioxytran. "To have consistently targeted undetectable viral presence by Polymerase Chain Reaction (PCR) in such a short timeframe across multiple trials is a remarkable achievement. As the first oral antiviral based on the power of sugar chemistry, ProLectin-M is on track to deliver a therapeutic that could fundamentally change how the world manages viral outbreaks."
About Bioxytran, Inc.
Bioxytran, Inc. is at the forefront of developing linear complex carbohydrate-based therapeutics to address critical unmet medical needs in its antiviral platform technology.
For more information, visit www.bioxytraninc.com
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words "believe," "expect," "anticipate," "estimate," "intend," "plan," and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran's actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
